Analyst Michael Ulz of Morgan Stanley maintained a Hold rating on BioAge Labs, Inc., retaining the price target of $23.00.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Michael Ulz has given his Hold rating due to a combination of factors reflecting both promising clinical momentum and a still-early risk profile. BioAge is advancing BGE-102 on schedule, with a Phase 2a cardiovascular outcomes study and an ophthalmology trial planned for 2026, supported by encouraging early data that suggest competitive potential but still require formal proof-of-concept validation.
At the same time, much of the company’s value depends on BGE-102 and a next-generation APJ agonist pipeline that remains in preclinical or early clinical stages, leaving significant execution and development risk. While the balance sheet is strong enough to fund operations into 2029, the current valuation appears to adequately reflect both upside from upcoming catalysts and the inherent uncertainties, leading Ulz to recommend investors maintain positions rather than aggressively add exposure for now.
Ulz covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, Arrowhead Pharmaceuticals, and Sarepta Therapeutics. According to TipRanks, Ulz has an average return of 0.9% and a 43.13% success rate on recommended stocks.
In another report released today, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $16.00 price target.